Bristol-Myers Fights Investor Pushback On $74B Celgene Buy
Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene in a letter to employees disclosed Thursday, after one of its top shareholders publicly contended the pharmaceutical giant is overpaying and...To view the full article, register now.
Already a subscriber? Click here to view full article